JP2003300870A - Ubiquinone-containing water-soluble composition - Google Patents
Ubiquinone-containing water-soluble compositionInfo
- Publication number
- JP2003300870A JP2003300870A JP2002335272A JP2002335272A JP2003300870A JP 2003300870 A JP2003300870 A JP 2003300870A JP 2002335272 A JP2002335272 A JP 2002335272A JP 2002335272 A JP2002335272 A JP 2002335272A JP 2003300870 A JP2003300870 A JP 2003300870A
- Authority
- JP
- Japan
- Prior art keywords
- ubiquinone
- soluble composition
- containing water
- composition according
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Compositions Of Macromolecular Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、ユビキノンを含有
する水可溶性組成物およびその製造方法に関する。TECHNICAL FIELD The present invention relates to a water-soluble composition containing ubiquinone and a method for producing the same.
【０００２】[0002]
【従来の技術】ユビキノン、特にユビデカレノン（コエ
ンザイムＱ１０）は生体内の酸化還元反応に関与する電
子伝達物質ユビキノンの一種で、高等動物の体内に存在
し、医薬品または食品として有用である。より詳しく
は、ユビデカレノンはうっ血性心不全による浮腫、肺う
っ血や狭心症状等の治療を目的とした医薬品または健康
食品として有用である。2. Description of the Related Art Ubiquinone, especially ubidecarenone (Coenzyme Q10), is a kind of ubiquinone which is an electron carrier involved in redox reaction in the living body, is present in the body of higher animals, and is useful as a medicine or food. More specifically, ubidecarenone is useful as a medicine or health food for treating edema due to congestive heart failure, pulmonary congestion, angina, and the like.
【０００３】しかしながら、ユビキノンは脂溶性である
ため、ユビキノンを従来法により乳化して、例えば飲
料、ゼリー等水分含量の高い食品や水性医薬品製剤の原
料として使用すると、時間の経過とともに製品がネック
リング（分離）の現象を呈してしまい、製品に濁りが生
じ、商品価値を損なうという問題があった。このよう
に、ユビキノンを飲料等の水性食品や水性医薬品製剤に
使用することは困難であった。また、食品または医薬品
製剤の形態によっては乾燥タイプの固形剤が望まれる
が、結晶性ユビキノン粉末そのものでは光、酸素による
分解が促進される問題もあった。However, since ubiquinone is fat-soluble, if ubiquinone is emulsified by a conventional method and used as a raw material for foods and water-based pharmaceutical preparations having a high water content, such as beverages and jellies, the product necks over time. There is a problem that the phenomenon of (separation) is exhibited, the product becomes turbid, and the commercial value is impaired. Thus, it has been difficult to use ubiquinone in aqueous foods such as beverages and aqueous pharmaceutical preparations. Although a dry type solid agent is desired depending on the form of food or pharmaceutical preparation, the crystalline ubiquinone powder itself has a problem that decomposition by light and oxygen is promoted.
【０００４】このため、従来、医薬品の分野でユビキノ
ンは、錠剤、カプセル剤等の固形剤で使用されているの
みであり、特に飲料等の水を多量に含む食品や医薬品製
剤の製造に使用出来るような安定化されたユビキノン含
有水可溶性組成物は存在しなかった。For this reason, conventionally, ubiquinone has only been used as a solid agent such as tablets and capsules in the field of pharmaceuticals, and can be used particularly for the production of foods and pharmaceutical preparations containing a large amount of water such as beverages. No such stabilized ubiquinone-containing water-soluble composition was present.
【０００５】[0005]
【発明が解決しようとする課題】本発明の目的は、水を
含有する食品または医薬品の製造に使用されるユビキノ
ンを含有する安定化された水可溶性組成物、その製造方
法、当該ユビキノン水可溶性組成物を原料として製造さ
れる、ユビキノン含有製剤および該製剤を含む食品また
は医薬品を提供することにある。SUMMARY OF THE INVENTION An object of the present invention is to provide a stabilized water-soluble composition containing ubiquinone, which is used in the production of a food or drug containing water, a method for producing the same, and the ubiquinone water-soluble composition. An object of the present invention is to provide a ubiquinone-containing preparation and a food or medicine containing the preparation, which is produced from the product.
【０００６】[0006]
【課題を解決するための手段】脂溶性であるユビキノン
は水と単純混合すると、連続層と油層の比重が異なるた
め軽い油滴が上に分離（ネックリング）するという問題
を有している。本発明者らは、種々検討した結果、油滴
の平均粒子径を約８００ｎｍ以下、好ましくは約１５０
ｎｍ以下、より好ましくは約１００ｎｍ以下、最も好ま
しくは約５０ｎｍ以下程度に押さえることができれば上
記の問題を実質的に改善もしくは解決できることを見出
した。油滴の平均粒子径が約１５０ｎｍ以下であると得
られるユビキノン含有水可溶性組成物は完全に透明であ
る。約１５０ｎｍ〜８００ｎｍの場合は、ユビキノン含
有水可溶性組成物にわずかな濁りを生じることがある
が、実質的な問題はない。下限値は、原料の種類、原料
使用割合、使用する装置などにより異なるために一概に
はいえないが、通常５ｎｍ程度である。しかしながら下
限値は０ｎｍを越えさえすればこれに限られることはな
い。また、この程度の油滴径にするには油脂、乳化剤、
その溶解剤の種類と量、乳化法を明らかにすることで、
より優れた成果を得ることになることをも見出した。本
発明者らはこれらの知見に基づいて、さらに検討を重
ね、本発明を完成するに至った。Means for Solving the Problems Ubiquinone, which is fat-soluble, has a problem that when it is simply mixed with water, light oil droplets are separated (neck ring) due to the difference in specific gravity between the continuous layer and the oil layer. As a result of various studies, the present inventors have found that the average particle diameter of oil droplets is about 800 nm or less, preferably about 150 nm.
It has been found that the above problems can be substantially ameliorated or solved if the thickness can be controlled to be not more than about 100 nm, more preferably not more than about 100 nm, and most preferably not more than about 50 nm. The ubiquinone-containing water-soluble composition obtained when the average particle size of oil droplets is about 150 nm or less is completely transparent. In the case of about 150 nm to 800 nm, a slight turbidity may occur in the ubiquinone-containing water-soluble composition, but there is no substantial problem. The lower limit cannot be generally determined because it depends on the type of raw material, the raw material usage rate, the equipment used, etc., but is usually around 5 nm. However, the lower limit is not limited to this as long as it exceeds 0 nm. In addition, oils, emulsifiers,
By clarifying the type and amount of the dissolving agent and the emulsification method,
We also found that we would get better results. The present inventors have conducted further studies based on these findings and completed the present invention.
【０００７】すなわち、本発明は、（１） ユビキノン
を含有する油脂が、乳化剤溶液中に微分散していること
を特徴とするユビキノン含有水可溶性組成物、（２）
乳化剤溶液中に微分散しているユビキノンを含有する油
脂の粒子径が８００ｎｍ以下であることを特徴とする前
記（１）記載のユビキノン含有水可溶性組成物、（３）
アラビアガムまたは／およびゼラチンが乳化剤溶液中
に含まれていることを特徴とする前記（１）または
（２）に記載のユビキノン含有水可溶性組成物、（４）
組成物に対して０．５〜１５重量％のユビキノンを含
有していることを特徴とする前記（１）記載のユビキノ
ン含有水可溶性組成物、（５） 透明であり、かつ赤褐
色を呈している前記（１）〜（４）のいずれかに記載の
ユビキノン含有水可溶性組成物、（６） ユビキノンが
ユビデカレノンであることを特徴とする前記（）〜
（５）のいずれかに記載のユビキノン含有水可溶性組成
物、（７） 前記（１）〜（６）のいずれかに記載のユ
ビキノン含有水可溶性組成物の食品または医薬品製造の
ための使用、（８） ユビキノンを溶解した油脂と、乳
化剤溶液とを混合し、ユビキノンを含有する油脂を該溶
液中に微分散させることを特徴とするユビキノン含有水
可溶性組成物の製造方法、（９） ユビキノンを溶解し
た油脂が、ユビキノンを１〜７０重量％含有することを
特徴とする前記（８）記載のユビキノン含有水可溶性組
成物の製造方法、（１０） 乳化剤が、グリセリン脂肪
酸エステル、蔗糖、脂肪酸エステル、酵素分解レシチ
ン、アスコルビン酸パルミチン酸エステル、アラビアガ
ムおよびゼラチンから選ばれる１種または２種以上であ
る前記（８）または（９）記載のユビキノン含有水可溶
性組成物の製造方法、（１１） 乳化剤の使用量がユビ
キノンを溶解した油脂１００重量部に対し５〜１０００
重量部であることを特徴とする前記（８）〜（１０）の
いずれかに記載のユビキノン含有水可溶性組成物の製造
方法、（１２） ユビキノンを溶解する溶解剤がグリセ
リン、糖アルコールおよび水から選ばれる１種または２
種以上である前記（８）〜（１１）のいずれかに記載の
ユビキノン含有水可溶性組成物の製造方法、（１３）
乳化剤溶液とユビキノンを溶解した油脂の配合比が重量
比で９９：１〜７０：３０であることを特徴とする前記
（８）〜（１２）のいずれかに記載のユビキノン含有水
可溶性組成物の製造方法、（１４） 乳化剤溶液とユビ
キノンを溶解した油脂とを２０〜１００℃の温度で混合
し、ユビキノンを含有する油脂を該溶液中に微分散させ
ることを特徴とする前記（８）〜（１３）のいずれかに
記載のユビキノン含有水性組成物の製造方法、（１５）
ユビキノンがユビデカレノンであることを特徴とする
前記（８）〜（１４）のいずれかに記載のユビキノン含
有水性組成物の製造方法、（１６） 前記（１）〜
（６）のいずれかに記載のユビキノン含有水可溶性組成
物を乾燥させて得られるユビキノン含有製剤、（１７）
ユビキノンがユビデカレノンであることを特徴とする
前記（１６）記載のユビキノン含有製剤、（１８） 前
記（１）〜（６）のいずれかに記載のユビキノン含有水
可溶性組成物を噴霧乾燥させて得られるユビキノン含有
粉末製剤、（１９） ユビキノンがユビデカレノンであ
ることを特徴とする前記（１８）記載のユビキノン含有
粉末製剤、（２０） 前記（１）〜（６）のいずれかに
記載のユビキノン含有水可溶性組成物を噴霧冷却し、造
粒して得られるユビキノン含有ビーズ製剤、（２１）
ユビキノンがユビデカレノンであることを特徴とする前
記（２０）記載のユビキノン含有ビーズ製剤、（２２）
前記（１６）〜（２１）のいずれかに記載のユビキノ
ン含有製剤を含む食品または医薬品、に関する。That is, the present invention provides (1) a ubiquinone-containing water-soluble composition, characterized in that a fat or oil containing ubiquinone is finely dispersed in an emulsifier solution, (2)
The ubiquinone-containing water-soluble composition according to the above (1), characterized in that the oil and fat containing ubiquinone finely dispersed in the emulsifier solution has a particle size of 800 nm or less.
The ubiquinone-containing water-soluble composition according to the above (1) or (2), wherein gum arabic or / and gelatin is contained in the emulsifier solution.
The ubiquinone-containing water-soluble composition according to (1) above, which contains 0.5 to 15% by weight of ubiquinone with respect to the composition, (5) is transparent and has a reddish brown color. The ubiquinone-containing water-soluble composition according to any one of (1) to (4) above, (6) the ubiquinone is ubidecalenone, above () to
The ubiquinone-containing water-soluble composition according to any one of (5), (7) the use of the ubiquinone-containing water-soluble composition according to any one of (1) to (6) above for producing a food or a drug, ( 8) A method for producing a ubiquinone-containing water-soluble composition, which comprises mixing an oil / fat in which ubiquinone is dissolved with an emulsifier solution and finely dispersing an oil / fat containing ubiquinone in the solution, (9) Dissolving ubiquinone The oil and fat contains 1 to 70% by weight of ubiquinone, (8) The method for producing a ubiquinone-containing water-soluble composition according to (8), wherein the emulsifier is glycerin fatty acid ester, sucrose, fatty acid ester, enzyme (8) or (9) above, which is one or more selected from decomposed lecithin, ascorbyl palmitate, gum arabic and gelatin. (11) A method for producing a water-soluble composition containing ubiquinone, (11) The emulsifier is used in an amount of 5 to 1000 with respect to 100 parts by weight of oil and fat in which ubiquinone is dissolved.
The method for producing the ubiquinone-containing water-soluble composition according to any one of (8) to (10) above, wherein the ubiquinone-dissolving agent is glycerin, sugar alcohol and water. 1 or 2 chosen
(13) The method for producing a ubiquinone-containing water-soluble composition according to any one of (8) to (11), which is one or more species.
The ubiquinone-containing water-soluble composition according to any one of the above (8) to (12), characterized in that the mixing ratio of the emulsifier solution and the oil or fat in which ubiquinone is dissolved is 99: 1 to 70:30 by weight. Manufacturing method, (14) The emulsifier solution and the oil / fat in which ubiquinone is dissolved are mixed at a temperature of 20 to 100 ° C., and the oil / fat containing ubiquinone is finely dispersed in the solution (8) to (). (15) A method for producing the ubiquinone-containing aqueous composition according to any of (13),
Ubiquinone is ubidecalenone, The manufacturing method of the ubiquinone containing aqueous composition in any one of said (8)-(14), (16) Said (1)-
A ubiquinone-containing preparation obtained by drying the ubiquinone-containing water-soluble composition according to any one of (6), (17)
Ubiquinone is ubidecarenone, and is obtained by spray-drying the ubiquinone-containing water-soluble composition according to any one of (1) to (6) above, wherein the ubiquinone-containing preparation according to (16) above. Ubiquinone-containing powder formulation, (19) Ubiquinone-containing powder formulation according to (18), wherein ubiquinone is ubidecalenone, (20) Ubiquinone-containing water-soluble according to any one of (1) to (6) above. Ubiquinone-containing bead preparation obtained by spray cooling and granulating the composition, (21)
Ubiquinone-containing bead preparation according to the above (20), wherein the ubiquinone is ubidecarenone, (22)
The present invention relates to a food or drug containing the ubiquinone-containing preparation according to any of (16) to (21).
【０００８】[0008]
【発明の実施の形態】本発明に用いられるユビキノン
は、ユビキノンの有するイソプレン残基数が１〜１２の
ものが好適に用いられ、６〜１２のものがさらに好適に
用いられ、残基数が１０のもの（以下、ユビデカレノン
という）が特に好適に用いられる。ユビキノンは、公知
の方法によって製造して得ることができる。ユビキノン
の状態はいかなるものであってもよいが、結晶性である
ことが好ましい。本発明の原料として使用される、例え
ば油脂、乳化剤、溶解剤としては特別な制限はないが、
人または動物の健康に好ましくないものは使用されな
い。本発明のユビキノン含有水可溶性組成物およびユビ
キノン含有製剤の製造方法は、上記したとおりである
が、以下にその好ましい実施の態様をユビデカレノンを
例として説明する。BEST MODE FOR CARRYING OUT THE INVENTION The ubiquinone used in the present invention is preferably one having a number of isoprene residues of ubiquinone of 1 to 12, more preferably 6 to 12 and having a number of residues of Those of 10 (hereinafter referred to as ubidecarenone) are particularly preferably used. Ubiquinone can be produced and obtained by a known method. The ubiquinone may be in any state, but is preferably crystalline. There are no particular restrictions on the oils, fats, emulsifiers, and solubilizers used as the raw material of the present invention,
Nothing that is unfavorable to human or animal health is used. The method for producing the ubiquinone-containing water-soluble composition and the ubiquinone-containing preparation of the present invention is as described above, and a preferred embodiment thereof will be described below by taking ubidecarenone as an example.
【０００９】本発明におけるユビキノンを含有する油脂
に含まれるユビキノンの濃度は、約１〜７０重量％であ
る。但し、ユビキノンの濃度が高くなると冷却時固化
し、硬くなるので１０〜６０重量％が好ましく、２０〜
５０重量％がさらに好ましく、４０重量％が特に好まし
い。The concentration of ubiquinone contained in the fats and oils containing ubiquinone in the present invention is about 1 to 70% by weight. However, if the concentration of ubiquinone increases, it solidifies during cooling and becomes hard, so 10 to 60% by weight is preferable, and 20 to 20% by weight is preferable.
50% by weight is more preferable, and 40% by weight is particularly preferable.
【００１０】上記油脂としては、例えば大豆油、落花生
油、綿実油、タラ肝油、脂肪酸グリセライドなどを挙げ
ることができ、脂肪酸グリセライド、特に中鎖脂肪酸ト
リグリセライドが好ましく用いられる。中鎖脂肪酸トリ
グリセライドとしてはいずれのものでもよいが、脂肪酸
部分がカプリル酸、またはカプリン酸であるものが好ま
しく用いられる。また、中鎖脂肪酸トリグリセライドと
しては、市販されているものを用いてもよく、具体的に
は、例えばココナードＭＴ、ココナードＭＴ−Ｎ、ココ
ナードＲＫ（いずれも花王社製）、パナセート８００、
パナセート８１０、パナセート８７５（いずれも日本油
脂社製）等が挙げられるが、これらに限らない。なお、
ここで使用する油脂はその他に、例えば前記した以外の
植物油（ヤシ油、ナタネ油、ピーナッツ油、オリーブ油
等）、動物脂肪、魚油等も用いられる。Examples of the oils and fats include soybean oil, peanut oil, cottonseed oil, cod liver oil, and fatty acid glycerides, and fatty acid glycerides, particularly medium-chain fatty acid triglycerides are preferably used. Any medium-chain fatty acid triglyceride may be used, but one in which the fatty acid moiety is caprylic acid or capric acid is preferably used. As the medium-chain fatty acid triglyceride, commercially available ones may be used, and specifically, for example, Coconard MT, Coconard MT-N, Coconard RK (all manufactured by Kao Corporation), Panacet 800,
Examples thereof include Panacet 810 and Panacet 875 (both manufactured by NOF CORPORATION), but are not limited thereto. In addition,
Other fats and oils used here include, for example, vegetable oils (coconut oil, rapeseed oil, peanut oil, olive oil, etc.) other than those mentioned above, animal fats, fish oils and the like.
【００１１】本発明に用いられる乳化剤のＨＬＢ（親水
親油バランス）は通常は約７〜２０、好ましくは約１０
〜１６である。このような乳化剤としては、例えばグリ
セリン脂肪酸エステル、蔗糖脂肪酸エステル、酵素処理
レシチン、アスコルビン酸パルミチン酸エステル、アラ
ビアガム、ゼラチン等が挙げられ、単独で用いてもよい
し、あるいは２種類以上を併用してもよい。これらの乳
化剤を、ユビキノンを溶解した油脂１００重量部に対し
て約５〜１０００重量部、好ましくは約２０〜８００重
量部、更に好ましくは４０〜６００重量部添加して乳化
させることで、ユビキノンを含有する油脂が乳化剤溶液
中に微分散した、本発明のユビキノン含有水可溶性組成
物を得ることができる。なお、本発明において「微分
散」とは、ユビキノンを含有する微細な油脂が乳化剤中
に一様に分散していることを示す。本発明においては該
分散液をエマルションとよぶこともある。The HLB (hydrophilic / lipophilic balance) of the emulsifier used in the present invention is usually about 7 to 20, preferably about 10.
~ 16. Examples of such emulsifiers include glycerin fatty acid ester, sucrose fatty acid ester, enzyme-treated lecithin, ascorbyl palmitate, gum arabic, gelatin and the like, which may be used alone or in combination of two or more kinds. May be. These emulsifiers are added to about 5 to 1000 parts by weight, preferably about 20 to 800 parts by weight, and more preferably 40 to 600 parts by weight with respect to 100 parts by weight of fats and oils in which ubiquinone is dissolved, to emulsify the ubiquinone. The ubiquinone-containing water-soluble composition of the present invention in which the contained oils and fats are finely dispersed in the emulsifier solution can be obtained. In the present invention, "fine dispersion" means that fine oil and fat containing ubiquinone is uniformly dispersed in the emulsifier. In the present invention, the dispersion may be called an emulsion.
【００１２】上記乳化剤溶液の調整に使用される乳化剤
の溶解剤としては、グリセリン、エリスリトール、マル
チトール、キシリトールなどの糖アルコールもしくは水
またはそれらの混合物が挙げられる。その中でも、グリ
セリンが好ましい。使用される溶解剤の量は、乳化剤を
溶解させることのできる量であれば、いずれの量でもよ
い。溶解剤として水以外の溶解剤を用いて調製された本
発明のエマルションは保存安定性に優れ、且つ飲料中で
も透明に溶解し、ネックリングを生成しないので、水以
外の溶解剤を用いることが好ましい。しかしながら、水
を全く使用しないとエマルションの粘度が高く、ハンド
リングが悪くなるため適量の水を加えて粘度を下げるの
が好ましい。この場合は、ユビキノンを溶解した乳化剤
と溶解剤を含む溶液を混合し、攪拌した後に水を添加す
るのが好ましい。Examples of the emulsifier-dissolving agent used for preparing the emulsifier solution include sugar alcohols such as glycerin, erythritol, maltitol, and xylitol, water, or a mixture thereof. Among them, glycerin is preferable. The amount of the solubilizer used may be any amount as long as it can dissolve the emulsifier. The emulsion of the present invention prepared by using a solubilizer other than water as a solubilizer has excellent storage stability, and dissolves transparently in a beverage and does not form a neck ring. Therefore, it is preferable to use a solubilizer other than water. . However, if water is not used at all, the viscosity of the emulsion will be high and handling will be poor, so it is preferable to add an appropriate amount of water to reduce the viscosity. In this case, it is preferable to mix a solution containing an emulsifier in which ubiquinone is dissolved and a solution, and then add water after stirring.
【００１３】一方、粉末製剤、ビーズ製剤等を製造する
ために使用されるユビキノン含有水可溶性組成物を製造
するため使用される乳化剤の溶解剤としては、水を使用
するのが好ましい。On the other hand, it is preferable to use water as the solubilizer of the emulsifier used for producing the ubiquinone-containing water-soluble composition used for producing the powder formulation, the bead formulation and the like.
【００１４】なお、後述するように、ユビキノン含有粉
末製剤やビーズ製剤を製造する場合には例えば、フイル
ム形成能の良好な例えばアラビアガム、ゼラチン等のコ
ーティング剤を乳化剤溶液に添加することが好ましい。
この場合、粉末製剤、ビーズ製剤の生体内での溶解性が
極端に低下することがある。このような場合には、ユビ
キノンを含有する油脂を乳化剤溶液中に分散させるに際
し、コーティング剤と共に、例えば果糖、乳糖、砂糖等
の低分子糖類（単糖類、二糖類、オリゴ糖類など）を添
加するのが好ましい。その配合割合は製剤の種類やその
製造方法、および該製剤に要求される物性（例えば、溶
解性等）等により決まる。例えば、粉末製剤等を製造す
るには、溶解性を良くするためにかなりの量の糖を含ん
だものとするのが好ましい。一方、錠剤用のビーズを製
造する場合は、弾力性を強めるコーティング剤を多く配
合して圧縮耐性の強いものにするため、低分子糖類の割
合は相対的に少なくするのが好ましい。従って、コーテ
ィング剤、糖類の配合比率は厳密に決めがたく、要望さ
れる製剤物性によって大きく変わるので、予備試験を行
うことが好ましい。As will be described later, in the case of producing a ubiquinone-containing powder preparation or a bead preparation, it is preferable to add a coating agent such as gum arabic or gelatin having a good film forming ability to the emulsifier solution.
In this case, the in vivo solubility of the powder formulation and the bead formulation may be extremely reduced. In such a case, when dispersing an oil or fat containing ubiquinone in an emulsifier solution, a low-molecular-weight sugar such as fructose, lactose, or sugar (monosaccharide, disaccharide, oligosaccharide, etc.) is added together with the coating agent. Is preferred. The mixing ratio is determined by the type of preparation, the manufacturing method thereof, physical properties required for the preparation (eg, solubility), and the like. For example, in the case of producing a powder preparation or the like, it is preferable to contain a considerable amount of sugar in order to improve the solubility. On the other hand, when producing beads for tablets, it is preferable to relatively reduce the proportion of low-molecular-weight sugars in order to increase the compression resistance by incorporating a large amount of a coating agent that enhances elasticity. Therefore, the blending ratio of the coating agent and the saccharide cannot be strictly determined and greatly varies depending on the desired physical properties of the preparation. Therefore, it is preferable to conduct a preliminary test.
【００１５】表１に、粉末製剤、またはビーズ製剤を製
造する場合のコーティング剤（ゼラチンまたはアラビア
ガム）、低分子糖類、およびその他の成分（ユビキノ
ン、油脂、乳化剤ならびに溶解剤）の好ましい配合割合
の例を示す。Table 1 shows the preferable blending ratio of the coating agent (gelatin or gum arabic), the low molecular weight saccharide, and the other components (ubiquinone, fats and oils, emulsifiers and solubilizers) in the case of producing a powder formulation or a bead formulation. Here is an example:
【００１６】[0016]
【表１】
表中の％は、いずれも重量％を示している。この製剤の
乳化に使用される油脂および乳化剤の種類と量、ユビキ
ノンの溶解濃度はユビキノン含有水可溶性組成物の製造
方法に準ずるものである。なお、これら製剤を製造する
場合は、溶解剤として水を使用することが好ましい。こ
の例では、ゼラチンやアラビアガムがコーティング剤と
して使用されているが、ゼラチンやアラビアガムは上述
のとおり乳化剤としても使用されうる。ゼラチンやアラ
ビアガムはコーティング剤としてのみならず乳化剤とし
ても機能しうる。[Table 1] All percentages in the table indicate weight percentages. The types and amounts of oils and fats and emulsifiers used for emulsification of this preparation, and the dissolved concentration of ubiquinone are in accordance with the method for producing a ubiquinone-containing water-soluble composition. In addition, when manufacturing these preparations, it is preferable to use water as a dissolving agent. In this example, gelatin and gum arabic are used as coating agents, but gelatin and gum arabic can also be used as emulsifiers as described above. Gelatin and gum arabic can function not only as a coating agent but also as an emulsifier.
【００１７】次に、ユビキノンを溶解した油脂と、乳化
剤溶液、必要に応じてコーティング剤、低分子糖類とを
混合し、ユビキノンを乳化させる。エマルション中のユ
ビキノンを溶解した油脂液の割合が３０重量％以上にな
ると油滴粒子径が大きくなる場合がある。従って、乳化
剤溶液とユビキノンを含有する油脂の混合比は、重量比
で約９９：１〜約７０：３０程度、好ましくは約９５：
５〜約８０：２０程度である。この際、高濃度のユビキ
ノンを油脂に加熱溶解しても冷却すると固化するため、
乳化時も溶解時の温度を維持することが好ましい。この
温度はユビキノンの配合濃度にもよるが、最高約５０℃
で充分である。一方、溶解剤としてグリセリンを使用す
る無水乳化法では加温しないとかなり粘度が高い。その
ため、例えばユビキノンを１０ｋｇ以上使用するような
大量生産をする場合は約５０〜７０℃程度に加温するこ
とが好ましい。Next, the fats and oils in which ubiquinone is dissolved are mixed with an emulsifier solution, and if necessary, a coating agent and low molecular weight saccharides to emulsify ubiquinone. If the proportion of the oil / fat solution in which ubiquinone is dissolved in the emulsion is 30% by weight or more, the oil droplet particle size may increase. Therefore, the mixing ratio of the emulsifier solution and the fat / oil containing ubiquinone is about 99: 1 to about 70:30 by weight, preferably about 95 :.
It is about 5 to about 80:20. At this time, even if high-concentration ubiquinone is dissolved in oil and fat, it solidifies when cooled,
It is preferable to maintain the temperature during dissolution even during emulsification. This temperature depends on the compounding concentration of ubiquinone, but the maximum is about 50 ° C.
Is enough. On the other hand, in the anhydrous emulsification method using glycerin as the solubilizer, the viscosity is considerably high unless heated. Therefore, for example, in the case of mass production using 10 kg or more of ubiquinone, it is preferable to heat to about 50 to 70 ° C.
【００１８】これらの乳化には、例えばコロイドミル、
高速攪拌乳化機、高圧ホモゲナイザー（操作圧力約６０
０Ｋｇ／ｃｍ２前後）、超高圧ホモゲナイザー（操作圧
力約１０００Ｋｇ／ｃｍ２以上）、超音波ホモゲナイザ
ー等が使用される。大量生産の場合は、乳化を行う前に
予備乳化を行ってもよい。For emulsifying these, for example, a colloid mill,
High speed stirring emulsifier, high pressure homogenizer (operating pressure of about 60
0 Kg / cm 2 ), an ultra-high pressure homogenizer (operating pressure of about 1000 Kg / cm 2 or more), an ultrasonic homogenizer, etc. are used. In the case of mass production, preliminary emulsification may be performed before emulsification.
【００１９】エマルションの保存安定性は油滴粒子径分
布に左右されるが、粒子径分布がシャープなほど良好で
ある。コロイドミル、高速攪拌乳化機、超音波ホモゲナ
イザー等に比べ、高圧ホモゲナイザー、超高圧ホモゲナ
イザーを使用したエマルションの油滴粒子径分布は単一
ピークで狭く、且つ、粒子径は小さい。従って、長期保
存に耐え得る水可溶性ユビキノン製剤の乳化には、例え
ば高圧ホモゲナイザー、超高圧ホモゲナイザー等を使用
するのが好ましい。上記の方法によって得られるユビキ
ノン含有水可溶性組成物中のユビキノンの含有量は、
０．５〜１５重量％であることが好ましく、１〜１０重
量％であることが更に好ましい。The storage stability of the emulsion depends on the oil droplet particle size distribution, and the sharper the particle size distribution is, the better. Compared with a colloid mill, a high-speed stirring emulsifier, an ultrasonic homogenizer, etc., the emulsion using a high-pressure homogenizer and an ultra-high-pressure homogenizer has a narrow single-peak oil droplet particle size distribution and a small particle size. Therefore, for emulsification of the water-soluble ubiquinone preparation which can withstand long-term storage, it is preferable to use, for example, a high-pressure homogenizer, an ultra-high pressure homogenizer or the like. The content of ubiquinone in the ubiquinone-containing water-soluble composition obtained by the above method,
The amount is preferably 0.5 to 15% by weight, more preferably 1 to 10% by weight.
【００２０】本発明のユビキノン含有水可溶性組成物を
含有する製剤は、薬理学的に許容される１種もしくはそ
れ以上の担体と一緒に混合し、製剤学の技術分野におい
てよく知られている任意の方法により製造される。この
場合は例えば、乳糖、ブドウ糖、ショ糖、マンニット等
の賦形剤、澱粉、アルギン酸ナトリウム等の崩壊剤、ス
テアリン酸マグネシウム、タルク等の滑沢剤、ゼラチン
等の結合剤、脂肪酸エステル等の界面活性剤、グリセリ
ン等の可塑剤、ｐ−ヒドロキシ安息香酸エステル類等の
防腐剤、ｐＨ調整剤、香料もしくは着色料等がさらに含
有されていてもよい。また、本発明のユビキノン含有水
可溶性組成物は食品あるいは食品成分として用いられも
よく、例えば各種の栄養素、パルミチン酸レチノール、
トコフェロール、ビスベンチアミン、リボフラビン、塩
酸ピリドキリン、シアノコバラミン、コレカルシフェロ
ール、ニコチン酸アミド、パントテン酸カルシウム、葉
酸、ビオチン等のビタミン類、バニラエッセンス等の香
料、β−カロテン、二酸化チタン、クロロフィル等の着
色料、亜硫酸ナトリウム、亜硫酸水素ナトリウム、アス
コルビン酸ナトリウム、チオ硫酸ナトリウム等の酸化防
止剤、チーズやチョコレート等の風味物質または合成甘
味料等が含有されていてもよい。The formulation containing the ubiquinone-containing water-soluble composition of the present invention is mixed with one or more pharmaceutically acceptable carriers, and any of those well known in the technical field of pharmacy can be used. It is manufactured by the method. In this case, for example, excipients such as lactose, glucose, sucrose, mannitol, starch, disintegrating agents such as sodium alginate, lubricants such as magnesium stearate and talc, binders such as gelatin, fatty acid esters, etc. A surfactant, a plasticizer such as glycerin, a preservative such as p-hydroxybenzoic acid esters, a pH adjusting agent, a fragrance or a coloring agent, and the like may be further contained. Further, the ubiquinone-containing water-soluble composition of the present invention may be used as a food or a food component, for example, various nutrients, retinol palmitate,
Tocopherol, bisbentamine, riboflavin, pyridoxillin hydrochloride, cyanocobalamin, cholecalciferol, nicotinic acid amide, calcium pantothenate, vitamins such as folic acid and biotin, fragrances such as vanilla extract, β-carotene, titanium dioxide, chlorophyll coloring Additives, antioxidants such as sodium sulfite, sodium hydrogen sulfite, sodium ascorbate, and sodium thiosulfate, flavor substances such as cheese and chocolate, and synthetic sweeteners may be contained.
【００２１】本発明のユビキノン含有水可溶性組成物
は、液状の食品にはそのまま添加すれば良いが、例え
ば、粉末飲料、顆粒状食品等の粉末状の食品、粉末製剤
や錠剤等の場合には、該組成物を均一混合が可能な乳化
粉末、錠剤にあっては打錠圧力に耐え得るビーズ状に加
工することが望ましい。The ubiquinone-containing water-soluble composition of the present invention may be added as it is to a liquid food, but in the case of powdered foods such as powdered drinks and granular foods, powdered preparations and tablets, for example. It is desirable to process the composition into an emulsified powder capable of being uniformly mixed, and in the case of tablets, bead-shaped to withstand the tableting pressure.
【００２２】このような乳化粉末、ビーズ中のユビキノ
ンは微小な油滴となるため、表面を連続層の炭水化物、
蛋白質でコーティングして光、酸素による酸化に対する
耐性を強くするのが好ましい。そこで、酸素透過性の低
く、滑らかなフイルム形成能を有する炭水化物、例え
ば、砂糖、マルトース、グルコース、デキストリン、ア
ラビアガム、大豆ヘミセルロース等、蛋白質としてゼラ
チン、ミルクカゼイン等がコーティング剤として使用さ
れる。これらはコーティング剤として、乳化剤溶液に添
加するのが好ましい。Since ubiquinone in such emulsified powder and beads becomes minute oil droplets, the surface is covered with a continuous layer of carbohydrates,
It is preferably coated with a protein to enhance resistance to oxidation by light and oxygen. Therefore, carbohydrates having low oxygen permeability and a smooth film forming ability, such as sugar, maltose, glucose, dextrin, gum arabic, soybean hemicellulose, etc., gelatin as a protein, milk casein, etc. are used as a coating agent. These are preferably added to the emulsifier solution as a coating agent.
【００２３】本発明のユビキノン含有水可溶性組成物を
粉末化するには公知の方法に従ってよく、例えばカルボ
キシメチルセルロース、ヒドロキシエチルセルロース、
ヒドロキシプロピルセルロース、ヒドロキシプロピルメ
チルセルロース、ポリビニルアルコール、ポリビニルピ
ロリドン等の合成又は半合成高分子物質や、アラビアゴ
ム、トラガントゴム、ゼラチン等の天然高分子物質、粉
末乳糖、カゼイン、微結晶セルロース、澱粉、小麦粉、
デキストリン、二酸化硅素等の適当な増量剤を本発明の
水可溶性組成物に加え、噴霧乾燥、噴霧冷却、混練造
粒、凍結乾燥等の常法により行うことにより可能であ
り、さらにこうして得た粉末は適宜、錠剤もしくはハー
ドカプセル剤等の製剤の形態をとることができる。ある
いは、本発明のユビデカレノン水可溶性組成物を、グリ
セリン等の粘稠剤の添加により、ソフト（軟）カプセル
の形に製剤化することもできる。The ubiquinone-containing water-soluble composition of the present invention may be powdered by a known method, for example, carboxymethyl cellulose, hydroxyethyl cellulose,
Hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, synthetic or semi-synthetic polymeric substances such as polyvinylpyrrolidone, gum arabic, tragacanth gum, natural polymeric substances such as gelatin, powdered lactose, casein, microcrystalline cellulose, starch, wheat flour,
It is possible to add dextrin, a suitable extender such as silicon dioxide to the water-soluble composition of the present invention, and carry out by a conventional method such as spray drying, spray cooling, kneading granulation, freeze drying, and the like. Can be in the form of a preparation such as a tablet or a hard capsule. Alternatively, the ubidecarenone water-soluble composition of the present invention can be formulated into a soft capsule by adding a thickening agent such as glycerin.
【００２４】本発明のユビキノン含有水可溶性組成物の
摂取または投与量は、摂取または投与する人の性別、年
齢、健康状態等によって異なるので一概には言えず、含
有されているユビキノン含有水可溶性組成物の摂取また
は投与量が有効量となる公知の範囲から適宜選択すれば
よい。また摂取または投与回数は１日１回であっても、
または複数回であってもよい。The intake or dose of the ubiquinone-containing water-soluble composition of the present invention varies depending on the sex, age, health condition, etc. of the person who ingests or administers the ubiquinone-containing water-soluble composition. It may be appropriately selected from a known range in which the intake or dose of the substance is an effective amount. Moreover, even if the intake or administration frequency is once a day,
Alternatively, it may be plural times.
【００２５】ユビキノンは、小腸から吸収されるために
は一旦油脂類に溶解され、ミセル化されることが望まし
い。結晶性のユビキノンを単独経口摂取しても、吸収率
の低いことが知られている。本発明のユビキノン含有水
可溶性組成物は、液体製剤、マイクロカプセル、粉末製
剤等の粉末製剤、ビーズ製剤の何れの形態で使用されて
もよく、また食品に含有させて経口摂取した場合にも、
結晶性のユビキノンに比べ腸管からの吸収速度及び吸収
率が大幅に改善される。Ubiquinone is preferably dissolved in fats and oils and micelles in order to be absorbed from the small intestine. It is known that even if crystalline ubiquinone is ingested alone, the absorption rate is low. The ubiquinone-containing water-soluble composition of the present invention may be used in any form of liquid formulation, microcapsule, powder formulation such as powder formulation, bead formulation, and also when orally ingested in a food,
The absorption rate and absorption rate from the intestinal tract are greatly improved as compared with crystalline ubiquinone.
【００２６】[0026]
【実施例】以上の試験例および実施例ではユビデカレノ
ンはすべて協和発酵工業社製のものを用いた。EXAMPLES In the above test examples and examples, all ubidecarenones used were manufactured by Kyowa Hakko Kogyo Co., Ltd.
【００２７】〔試験例１〕溶解剤の種類とエマルション
の安定性
エースホモゲナイザー用５０ｍｌガラスカップにデカグ
リセリンモノオレエート（理研ビタミン社製）１．０
ｇ、および表２に示される溶解剤７．０ｇを加え、５０
℃に加温して乳化剤を分散溶解させた。一方、ユビデカ
レノン０．４ｇ、中鎖脂肪酸トリグリセライド（パナセ
ート８００、日本油脂社製）１．６ｇを混合し、４０℃
に加温しながらユビデカレノンの結晶を油脂に溶解させ
た。これを先のガラスカップに移し、１５０００ｒｐｍ
で１０分間攪拌し乳化させた。得られたユビデカレノン
を含有する乳化液を水で０．２％（ｖ／ｖ）に希釈し、
分光光度計で波長６６０ｎｍの濁度を測定した。さらに
該乳化液を４０℃で２ヶ月間保存し、同様に濁度を測定
した。一方、ＣＯＵＬＴＥＲ Ｎ４型サブミクロン粒子
分析装置（日科機社製）を用いて油滴の平均粒子径を測
定した。結果を表２に示した。表２に示されるように、
溶解剤としてグリセリンを用いた場合、希釈液の濁度は
乳化直後および２ヶ月間保存後のいずれにおいても低い
値を示した。また油滴の平均粒子径も最も小さかった。
なお、平均粒子径測定時の油滴の周りに厳密には乳化剤
が存在するが、乳化剤の膜は無視できる程度に薄いもの
であるから、実質的には油滴の径は乳化剤で覆われた油
滴の径と同一と考えてよい。Test Example 1 Type of Dissolving Agent and Stability of Emulsion Decaglycerin monooleate (manufactured by Riken Vitamin Co.) 1.0 in a 50 ml glass cup for an ace homogenizer.
g, and 7.0 g of the solubilizer shown in Table 2,
The emulsifier was dispersed and dissolved by heating to ℃. On the other hand, 0.4 g of ubidecarenone and 1.6 g of medium-chain fatty acid triglyceride (Panasate 800, manufactured by NOF CORPORATION) were mixed, and the mixture was mixed at 40 ° C.
The crystals of ubidecarenone were dissolved in the oil while heating. Transfer this to the previous glass cup, 15000rpm
And stirred for 10 minutes to emulsify. The obtained emulsion containing ubidecarenone was diluted with water to 0.2% (v / v),
Turbidity at a wavelength of 660 nm was measured with a spectrophotometer. Further, the emulsion was stored at 40 ° C. for 2 months, and the turbidity was measured in the same manner. On the other hand, the average particle diameter of the oil droplets was measured using a COULTER N4 type submicron particle analyzer (manufactured by Nikkaki Co., Ltd.). The results are shown in Table 2. As shown in Table 2,
When glycerin was used as the solubilizer, the turbidity of the diluted solution was low both immediately after emulsification and after storage for 2 months. The average particle size of oil droplets was also the smallest.
Although the emulsifier is strictly present around the oil droplets at the time of measuring the average particle diameter, the film of the emulsifier is so thin that it can be ignored, so the diameter of the oil droplets is substantially covered with the emulsifier. It can be considered to be the same as the diameter of the oil droplet.
【００２８】[0028]
【表２】
※１：（ ）内は溶解剤の水分含量。以下マルチトー
ル、ソルビトールおよびグリセリンの場合も同様。[Table 2] * 1: The content in () is the water content of the dissolving agent. The same applies to maltitol, sorbitol and glycerin below.
【００２９】〔実施例１〕４ｇのユビデカレノンを３６
ｇのオリーブ油に分散し４０℃で加温溶解し、ユビデカ
レノンのオリーブ油溶液を得た。一方、デカグリセリン
モノラウレート１８ｇ、酵素分解レシチン２ｇをグリセ
リン１１０ｇに分散溶解させ、５０℃に加温した。この
グリセリン溶液をＴＫホモミキサー（ＴＫ ＨＯＭＯ
ＭＩＸＥＲＭＡＲＫ ＩＩ、特殊機械工業社製）で攪拌
しながらユビデカレノンのオリーブ油溶液を加えた。こ
れを５０℃、５０００ｒｐｍで１０分間予備乳化した。
次いで、高圧ホモゲナイザー（ウエストファリアセパレ
ーター社製卓上乳化器）を使用し、乳化圧力５００Ｋｇ
／ｃｍ２、処理回数３回リサイクルでエマルションを調
製した。このエマルションをビーカーに移し３０℃以下
まで冷却し、ＴＫホモミキサーで１０００ｒｐｍ程度の
攪拌をしながら水３０ｍｌを加えた。得られたエマルシ
ョンは２重量％のユビデカレノンを含有し、油滴の平均
粒子径７０ｎｍの透明で、赤褐色を呈するものであっ
た。Example 1 4 g of ubidecarenone was added to 36 g.
g of olive oil and dissolved by heating at 40 ° C. to obtain a solution of ubidecarenone in olive oil. On the other hand, 18 g of decaglycerin monolaurate and 2 g of enzymatically decomposed lecithin were dispersed and dissolved in 110 g of glycerin and heated to 50 ° C. This glycerin solution was mixed with TK homomixer (TK HOMO
A solution of ubidecarenone in olive oil was added while stirring with MIXERMARK II, manufactured by Tokushu Kikai Kogyo KK. This was pre-emulsified at 50 ° C. and 5000 rpm for 10 minutes.
Then, using a high-pressure homogenizer (tabletop emulsifier manufactured by Westfalia Separator), emulsification pressure 500 Kg
/ Cm 2 , and the number of treatments was recycled 3 times to prepare an emulsion. This emulsion was transferred to a beaker, cooled to 30 ° C. or lower, and 30 ml of water was added while stirring at about 1000 rpm with a TK homomixer. The obtained emulsion contained 2% by weight of ubidecarenone, was transparent with a mean particle size of oil droplets of 70 nm, and was reddish brown.
【００３０】〔実施例２〕１６ｇのユビデカレノンを２
４ｇの中鎖脂肪酸トリグリセライド（エコナードＭＴ、
花王社製）に分散し５０℃で加温溶解し、ユビデカレノ
ンの中鎖脂肪酸トリグリセライド溶液を得た。一方、デ
カグリセリンモノオレエート（理研ビタミン社製）１８
ｇ、酵素分解レシチン（Ｔ＆Ｋレシチン社製）２ｇをグ
リセリン１１０ｇ、水３０ｇの溶液に分散溶解させて５
０℃に加温した。このグリセリン水溶液をＴＫホモミキ
サーで攪拌しながらユビデカレノンの中鎖脂肪酸トリグ
リセライド溶液を加えた。これを５０℃、５０００ｒｐ
ｍで１０分間予備乳化した。次いで、高圧ホモゲナイザ
ー（ウエストファリアセパレーター社製卓上乳化器）を
使用し、乳化圧力７００Ｋｇ／ｃｍ２、処理回数３回リ
サイクルでエマルションを調製した。このエマルション
をビーカーに移し３０℃以下まで冷却した。得られたエ
マルションは８重量％のユビデカレノンを含有し、油滴
の平均粒子径９０ｎｍの透明で、赤褐色を呈するもので
あった。Example 2 16 g of ubidecarenone was added to 2
4 g of medium chain fatty acid triglyceride (Econard MT,
The product was dispersed in Kao Corporation and dissolved by heating at 50 ° C. to obtain a medium chain fatty acid triglyceride solution of ubidecarenone. On the other hand, decaglycerin monooleate (manufactured by Riken Vitamin Co.) 18
g, 2 g of enzymatically decomposed lecithin (manufactured by T & K lecithin) is dispersed and dissolved in a solution of 110 g of glycerin and 30 g of water to prepare 5
Warmed to 0 ° C. This glycerin aqueous solution was added with a medium chain fatty acid triglyceride solution of ubidecarenone while stirring with a TK homomixer. This is 50 ℃, 5000 rp
m for 10 minutes. Then, using a high-pressure homogenizer (tabletop emulsifier manufactured by Westfalia Separator), an emulsion was prepared by emulsifying pressure of 700 Kg / cm 2 and recycling three times. This emulsion was transferred to a beaker and cooled to 30 ° C or lower. The obtained emulsion contained 8% by weight of ubidecarenone, was transparent with a mean particle size of oil droplets of 90 nm, and was reddish brown.
【００３１】〔実施例３〕上記実施例２においてグリセ
リンと水の代りにマルチトール１４０ｇを使用した以外
は同じ方法でエマルションを製造した。得られたエマル
ションの油滴の平均粒子径は１００ｎｍの透明で、濃赤
褐色を呈するものであった。Example 3 An emulsion was prepared in the same manner as in Example 2 except that 140 g of maltitol was used instead of glycerin and water. The average particle diameter of the oil droplets of the obtained emulsion was 100 nm, which was transparent and had a deep reddish brown color.
【００３２】〔実施例４〕ユビデカレノン４０ｇを中鎖
脂肪酸トリグリセライド（パナセート８００、日本油脂
社製）６０ｇに分散し、５０℃で加温し溶解させ、ユビ
デカレノンの中鎖脂肪酸トリグリセライド溶液を得た。
一方、砂糖５００ｇ、ゼラチン３５０ｇ、アスコルビン
酸パルミテート（日本ロシュ社製）４０ｇ、抗酸化剤で
あるイーミックス（８０）（理研ビタミン社製）１０ｇ
を水２０００ｍｌに加えて７０℃で分散溶解させた。こ
の溶液をＴＫホモミキサーで攪拌しながらユビデカレノ
ンの中鎖脂肪酸トリグリセライド溶液を加えた。これを
５０〜６０℃、６０００ｒｐｍで３０分間乳化した。[Example 4] 40 g of ubidecarenone was dispersed in 60 g of medium-chain fatty acid triglyceride (Panasate 800, manufactured by NOF CORPORATION), and the mixture was heated and dissolved at 50 ° C to obtain a medium-chain fatty acid triglyceride solution of ubidecarenone.
On the other hand, 500 g of sugar, 350 g of gelatin, 40 g of ascorbic acid palmitate (manufactured by Nippon Roche), 10 g of E-mix (80) (manufactured by Riken Vitamin) which is an antioxidant.
Was added to 2000 ml of water and dispersed and dissolved at 70 ° C. This solution was added with a medium chain fatty acid triglyceride solution of ubidecarenone while stirring with a TK homomixer. This was emulsified at 50-60 ° C. and 6000 rpm for 30 minutes.
【００３３】〔実施例５〕ユビデカレノン４０ｇを中鎖
脂肪酸トリグリセライド（パナセート８００、日本油脂
社製）６０ｇに分散し、５０℃で加温し溶解させ、ユビ
デカレノンの中鎖脂肪酸トリグリセライド溶液を得た。
一方、砂糖５００ｇ、ゼラチン３５０ｇ、アスコルビン
酸パルミテート（日本ロシュ社製）４０ｇ、イーミック
ス（８０）（理研ビタミン社製）１０ｇを水２０００ｍ
ｌに加えて７０℃で分散溶解させた。この溶液をＴＫホ
モミキサーで攪拌しながらユビデカレノンの中鎖脂肪酸
トリグリセライド溶液を加えた。これを５０〜６０℃、
５０００ｒｐｍで１０分間予備乳化した。次いで高圧ホ
モゲナイザーを使用し（乳化圧力６００Ｋｇ／ｃｍ２、
処理回数２回リサイクル）でエマルションを調製した。
得られたエマルションを噴霧乾燥機（Ｌ−１２型、大川
原加工機社製）でディスク回転数２，０００ｒｐｍ、入
り口熱風温度１６０〜１７０℃、出口温度約８５℃の条
件下で噴霧乾燥して粉末を得た。この粉末中の油滴の平
均粒子径は１５０ｎｍであった。[Example 5] 40 g of ubidecarenone was dispersed in 60 g of medium-chain fatty acid triglyceride (Panasate 800, manufactured by NOF CORPORATION), and the mixture was heated and dissolved at 50 ° C to obtain a medium-chain fatty acid triglyceride solution of ubidecarenone.
On the other hand, 500 g of sugar, 350 g of gelatin, 40 g of ascorbic acid palmitate (manufactured by Nippon Roche), 10 g of e-mix (80) (manufactured by Riken Vitamin) and 2000 m of water.
In addition to 1, the mixture was dispersed and dissolved at 70 ° C. This solution was added with a medium chain fatty acid triglyceride solution of ubidecarenone while stirring with a TK homomixer. 50 ~ 60 ℃,
It was pre-emulsified at 5000 rpm for 10 minutes. Then using a high pressure homogenizer (emulsification pressure 600 Kg / cm 2 ,
An emulsion was prepared by repeating the treatment twice.
The obtained emulsion was spray-dried with a spray dryer (L-12 type, manufactured by Okawara Koki Co., Ltd.) under the conditions of a disk rotation speed of 2,000 rpm, an inlet hot air temperature of 160 to 170 ° C, and an outlet temperature of about 85 ° C. Got The average particle size of the oil droplets in this powder was 150 nm.
【００３４】〔実施例６〕ユビデカレノン１０ｇをヤシ
油１５ｇに分散し、５０℃で加温溶解させて、ユビデカ
レノンのヤシ油溶液を得た。一方、砂糖１５ｇ、ゼラチ
ン５５ｇ、アスコルビン酸パルミテート４ｇ、イーミッ
クス（８０）（理研ビタミン社製）１ｇを水２５０ｍｌ
に分散し、５０℃で溶解させた。このゼラチン溶液をＴ
Ｋホモゲナイザーで攪拌しながら先のユビデカレノンの
ヤシ油溶液を加えた。これを５０〜６０℃、６０００ｒ
ｐｍで３０分間乳化した。得られたエマルションを図１
に示した装置を用いて０．５〜１ｍｍ前後の液滴を造り
ながら約０℃の冷却気流中で急速冷却した。固化した含
水ビーズを流動層乾燥機（フローコーターミニ、フロイ
ント産業社製）を使い、３０℃以下の乾燥空気で乾燥し
た。水分が少なくなるにしたがって乾燥温度を上昇さ
せ、最終的に７０℃まで高めて約１時間乾燥させて、含
水率が５％以下になるまで乾燥させた。このようにして
得られたビーズは１０重量％のユビデカレノンを含有
し、３トンの高い圧力を負荷した打錠工程を経た錠剤中
においても 破壊されなかった。Example 6 10 g of ubidecarenone was dispersed in 15 g of coconut oil and dissolved by heating at 50 ° C. to obtain a coconut oil solution of ubidecarenone. On the other hand, sugar 15g, gelatin 55g, ascorbic acid palmitate 4g, Emix (80) (manufactured by Riken Vitamin) 1g 250ml of water
And was dissolved at 50 ° C. This gelatin solution is T
The ubidecarenone coconut oil solution was added while stirring with a K homogenizer. This is 50-60 ℃, 6000r
Emulsified at pm for 30 minutes. The resulting emulsion is shown in FIG.
Rapid cooling was performed in a cooling airflow of about 0 ° C. while forming droplets of about 0.5 to 1 mm using the device shown in FIG. The solidified water-containing beads were dried with dry air at 30 ° C. or lower using a fluidized bed dryer (Flow Coater Mini, manufactured by Freund Sangyo Co., Ltd.). The drying temperature was raised as the water content decreased, and finally the temperature was raised to 70 ° C. and dried for about 1 hour until the water content became 5% or less. The beads thus obtained contained 10% by weight of ubidecarenone, and were not broken even in the tablets that had undergone the tableting process under a high pressure of 3 tons.
【００３５】さらに、図１に示す装置について付言す
る。図１のような円盤の外周に穴が開いた円盤を低速回
転１００〜１２０ｒｐｍ／分程度の速度で回転させる。
円盤内にエマルションを連続的に供給し、円盤の回転で
生じる遠心力で小さな液滴を造る。この円盤の遠心力は
円盤の回転数によって変わる。従って、円盤の回転数は
目的とするビーズの粒径により変動するので、その都度
適宜調製するとよい。ここで造られた小さな液滴は０℃
前後の冷却空気の中に連続的に供給され、急速に冷却さ
れるので乳化液中のゼラチンが固化し小さなビーズが得
られる。得られたビーズをさらに乾燥させて製剤化す
る。Further, the device shown in FIG. 1 will be additionally described. A disc having a hole on the outer periphery of the disc as shown in FIG. 1 is rotated at a low speed of about 100 to 120 rpm / min.
The emulsion is continuously fed into the disk and the centrifugal force generated by the rotation of the disk creates small droplets. The centrifugal force of this disk changes depending on the rotation speed of the disk. Therefore, the number of rotations of the disk varies depending on the particle diameter of the target beads, and it may be appropriately adjusted each time. The small droplets created here are 0 ° C
The gelatin in the emulsion is solidified and small beads are obtained because it is continuously supplied into the front and rear cooling air and is rapidly cooled. The obtained beads are further dried and formulated.
【００３６】〔実施例７〕ユビデカレノン４ｇを中鎖脂
肪酸トリグリセライド（パナセート８００、日本油脂社
製）６ｇに分散し、５０℃で加温して溶解させ、ユビデ
カレノンの中鎖脂肪酸トリグリセライド溶液を得た。一
方、アラビアガム（アラビックコールＳＳ、三栄薬品社
製）５８ｇ、砂糖３０ｇ、Ｌ−アスコルビン酸ナトリウ
ム（日本ロシュ社製）０．３ｇ、イーミックス（８０）
（理研ビタミン社製）０．１ｇを水１７０ｇに加えて７
０℃で分散し分散液を得た。該分散液をＴＫホモミキサ
ーで攪拌しながらユビデカレノンの中鎖脂肪酸トリグリ
セライド溶液を添加し、６０℃、６０００ｒｐｍで３０
分間予備乳化した。該予備乳化液を高圧ホモゲナイザー
を使用して、乳化圧力８００ｋｇ／ｃｍ２で３回リサイ
クル処理し、乳化液を得た。該乳化液を噴霧乾燥機（Ｌ
−１２型、大川原加工機社製）で熱風入り口温度１８０
℃、排風温度８５℃で噴霧乾燥し、粉末７０ｇを得た。
該粉末は、４重量％のユビデカレノンを含有した。乳化
粒子は平均粒子径４２６ｎｍであった（ＣＯＵＬＴＥＲ
Ｎ４型サブミクロン粒子分析装置（日科機社製））。
該粉末は水への分散性が良好で、５重量％まで分散可能
であった。また、該分散液をｐＨ３〜７に調整し、４０
℃で３ヶ月間保温しても、油層の分離等は生じず、平均
粒子径も変わらなかった。Example 7 4 g of ubidecarenone was dispersed in 6 g of medium-chain fatty acid triglyceride (Panasate 800, manufactured by NOF CORPORATION) and dissolved by heating at 50 ° C. to obtain a medium-chain fatty acid triglyceride solution of ubidecarenone. On the other hand, gum arabic (Arabic Cole SS, Sanei Pharmaceutical Co., Ltd.) 58 g, sugar 30 g, sodium L-ascorbate (Nippon Roche Co., Ltd.) 0.3 g, Emix (80)
Add 0.1 g (manufactured by Riken Vitamin Co.) to 170 g of water and add 7
Dispersion was performed at 0 ° C. to obtain a dispersion. While the dispersion was stirred with a TK homomixer, a medium chain fatty acid triglyceride solution of ubidecarenone was added, and the mixture was added at 60 ° C. and 6000 rpm for 30 minutes.
It was pre-emulsified for a minute. The preliminary emulsified liquid was recycled three times using a high pressure homogenizer at an emulsifying pressure of 800 kg / cm 2 to obtain an emulsified liquid. The emulsion was spray dried (L
-12 type, Okawara Koki Co., Ltd.) hot air inlet temperature 180
C., the temperature of the exhaust air was 85.degree. C., and spray-dried to obtain 70 g of powder.
The powder contained 4% by weight ubidecarenone. The emulsified particles had an average particle size of 426 nm (COULTER
N4 type submicron particle analyzer (manufactured by Nikkaki Co., Ltd.).
The powder had good dispersibility in water and could be dispersed up to 5% by weight. Further, the pH of the dispersion is adjusted to 3 to 7,
Even when kept at 3 ° C. for 3 months, separation of the oil layer did not occur and the average particle size did not change.
【００３７】[0037]
【発明の効果】本発明によって、ユビキノンを含有する
油脂が乳化剤溶液中に微分散しているユビキノンを含有
する水可溶性組成物が提供される。これらは、それ自
体、食品、医薬品として、または食品、医薬品の原料と
して有用である。The present invention provides a water-soluble composition containing ubiquinone in which an oil or fat containing ubiquinone is finely dispersed in an emulsifier solution. These are useful per se as foods, pharmaceuticals, or as raw materials for foods and pharmaceuticals.
【図１】 図１は、ユビキノン含有ビーズ製剤を製造す
るための装置の概略図である。FIG. 1 is a schematic diagram of an apparatus for producing a ubiquinone-containing bead formulation.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ６１Ｋ 47/10 Ａ６１Ｋ 47/10 47/14 47/14 47/22 47/22 47/24 47/24 47/26 47/26 47/42 47/42 47/44 47/44 47/48 47/48 Ａ６１Ｐ 3/02 １０９ Ａ６１Ｐ 3/02 １０９ 7/10 7/10 9/04 9/04 9/10 9/10 11/00 11/00 Ｃ０８Ｊ 3/02 ＣＦＪ Ｃ０８Ｊ 3/02 ＣＦＪＡ Ｃ０８Ｌ 91/00 Ｃ０８Ｌ 91/00 93/00 93/00 Ｆターム(参考） 4B018 MD07 MD09 MD20 MD37 ME14 MF02 4C076 AA17 AA29 AA30 AA31 BB01 CC11 CC15 CC23 CC40 DD38 DD45 DD46 DD59 DD63 DD67 EE42 EE52 EE58 FF36 FF37 FF43 FF51 FF63 FF64 FF65 FF68 4C206 AA01 AA02 CB27 MA03 MA05 MA42 MA61 MA63 MA72 NA03 NA10 ZA36 ZA59 ZC29 4F070 AA63 AA64 AA72 AC96 AE14 AE28 CA12 CA18 CA19 CB03 CB04 CB12 CB13 4J002 AC06X AE05W AF03X AJ00X FD20X GB01 GC00 HA07─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 7 Identification code FI theme code (reference) A61K 47/10 A61K 47/10 47/14 47/14 47/22 47/22 47/24 47/24 47 / 26 47/26 47/42 47/42 47/44 47/44 47/48 47/48 A61P 3/02 109 A61P 3/02 109 7/10 7/10 9/04 9/04 9/10 9 / 10 11/00 11/00 C08J 3/02 CFJ C08J 3/02 CFJA C08L 91/00 C08L 91/00 93/00 93/00 F term (reference) 4B018 MD07 MD09 MD20 MD37 ME14 MF02 4C076 AA17 AA29 AA30 AA31 BB01 CC11 CC15 CC23 CC40 DD38 DD45 DD46 DD59 DD63 DD67 EE42 EE52 EE58 FF36 FF37 FF43 FF51 FF63 FF64. AC06X AE05W AF03X AJ00X FD20X GB01 GC00 HA07
Claims (22)
液中に微分散していることを特徴とするユビキノン含有
水可溶性組成物。1. A ubiquinone-containing water-soluble composition, wherein an oil and fat containing ubiquinone is finely dispersed in an emulsifier solution.
ンを含有する油脂の粒子径が８００ｎｍ以下であること
を特徴とする請求項１記載のユビキノン含有水可溶性組
成物。2. The ubiquinone-containing water-soluble composition according to claim 1, wherein the oil and fat containing ubiquinone finely dispersed in the emulsifier solution has a particle size of 800 nm or less.
乳化剤溶液中に含まれていることを特徴とする請求項１
または２に記載のユビキノン含有水可溶性組成物。3. Gum arabic and / or gelatin are contained in the emulsifier solution.
Alternatively, the ubiquinone-containing water-soluble composition according to item 2.
ビキノンを含有していることを特徴とする請求項１記載
のユビキノン含有水可溶性組成物。4. The ubiquinone-containing water-soluble composition according to claim 1, which contains 0.5 to 15% by weight of ubiquinone with respect to the composition.
求項１〜４のいずれかに記載のユビキノン含有水可溶性
組成物。5. The ubiquinone-containing water-soluble composition according to any one of claims 1 to 4, which is transparent and has a reddish brown color.
を特徴とする請求項１〜５のいずれかに記載のユビキノ
ン含有水可溶性組成物。6. The ubiquinone-containing water-soluble composition according to claim 1, wherein the ubiquinone is ubidecarenone.
ノン含有水可溶性組成物の食品または医薬品製造のため
の使用。7. Use of the ubiquinone-containing water-soluble composition according to any one of claims 1 to 6 for producing a food or a drug.
液とを混合し、ユビキノンを含有する油脂を該溶液中に
微分散させることを特徴とするユビキノン含有水可溶性
組成物の製造方法。8. A method for producing a ubiquinone-containing water-soluble composition, which comprises mixing an oil / fat in which ubiquinone is dissolved with an emulsifier solution and finely dispersing the oil / fat containing ubiquinone in the solution.
ンを１〜７０重量％含有することを特徴とする請求項８
記載のユビキノン含有水可溶性組成物の製造方法。9. The ubiquinone-dissolved oil or fat contains 1 to 70% by weight of ubiquinone.
A method for producing the ubiquinone-containing water-soluble composition as described.
ル、蔗糖、脂肪酸エステル、酵素分解レシチン、アスコ
ルビン酸パルミチン酸エステル、アラビアガムおよびゼ
ラチンから選ばれる１種または２種以上である請求項８
または９記載のユビキノン含有水可溶性組成物の製造方
法。10. The emulsifier is one or more selected from glycerin fatty acid ester, sucrose, fatty acid ester, enzymatically decomposed lecithin, ascorbyl palmitate, gum arabic and gelatin.
Or the method for producing the ubiquinone-containing water-soluble composition according to item 9.
た油脂１００重量部に対し５〜１０００重量部であるこ
とを特徴とする請求項８〜１０のいずれかに記載のユビ
キノン含有水可溶性組成物の製造方法。11. The ubiquinone-containing water-soluble composition according to any one of claims 8 to 10, wherein the amount of the emulsifier used is 5 to 1000 parts by weight based on 100 parts by weight of the ubiquinone-dissolved oil and fat. Production method.
リン、糖アルコールおよび水から選ばれる１種または２
種以上である請求項８〜１１のいずれかに記載のユビキ
ノン含有水可溶性組成物の製造方法。12. The dissolving agent for dissolving ubiquinone is one or two selected from glycerin, sugar alcohol and water.
The method for producing a ubiquinone-containing water-soluble composition according to any one of claims 8 to 11, which comprises at least one species.
脂の配合比が重量比で９９：１〜７０：３０であること
を特徴とする請求項８〜１２のいずれかに記載のユビキ
ノン含有水可溶性組成物の製造方法。13. The ubiquinone-containing water-soluble composition according to claim 8, wherein the compounding ratio of the emulsifier solution and the oil or fat in which ubiquinone is dissolved is 99: 1 to 70:30 by weight. Method of manufacturing things.
脂とを２０〜１００℃の温度で混合し、ユビキノンを含
有する油脂を該溶液中に微分散させることを特徴とする
請求項８〜１３のいずれかに記載のユビキノン含有水性
組成物の製造方法。14. The emulsifier solution and the oil or fat in which ubiquinone is dissolved are mixed at a temperature of 20 to 100 ° C., and the oil or fat containing ubiquinone is finely dispersed in the solution. A method for producing the ubiquinone-containing aqueous composition according to claim 1.
とを特徴とする請求項８〜１４のいずれかに記載のユビ
キノン含有水性組成物の製造方法。15. The method for producing an ubiquinone-containing aqueous composition according to claim 8, wherein the ubiquinone is ubidecarenone.
キノン含有水可溶性組成物を乾燥させて得られるユビキ
ノン含有製剤。16. A ubiquinone-containing preparation obtained by drying the ubiquinone-containing water-soluble composition according to any one of claims 1 to 6.
とを特徴とする請求項１６記載のユビキノン含有製剤。17. The ubiquinone-containing preparation according to claim 16, wherein the ubiquinone is ubidecarenone.
キノン含有水可溶性組成物を噴霧乾燥させて得られるユ
ビキノン含有粉末製剤。18. A ubiquinone-containing powder preparation obtained by spray drying the ubiquinone-containing water-soluble composition according to any one of claims 1 to 6.
とを特徴とする請求項１８記載のユビキノン含有粉末製
剤。19. The ubiquinone-containing powder preparation according to claim 18, wherein the ubiquinone is ubidecarenone.
キノン含有水可溶性組成物を噴霧冷却し、造粒して得ら
れるユビキノン含有ビーズ製剤。20. A ubiquinone-containing bead preparation obtained by spray-cooling and granulating the ubiquinone-containing water-soluble composition according to any one of claims 1 to 6.
とを特徴とする請求項２０記載のユビキノン含有ビーズ
製剤。21. The ubiquinone-containing bead preparation according to claim 20, wherein the ubiquinone is ubidecarenone.
ユビキノン含有製剤を含む食品または医薬品。22. A food or drug containing the ubiquinone-containing preparation according to claim 16.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002335272A JP4429590B2 (en) | 2002-02-08 | 2002-11-19 | Ubiquinone-containing water-soluble composition |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002-33135 | 2002-02-08 | ||
| JP2002033135 | 2002-02-08 | ||
| JP2002335272A JP4429590B2 (en) | 2002-02-08 | 2002-11-19 | Ubiquinone-containing water-soluble composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003300870A true JP2003300870A (en) | 2003-10-21 |
| JP2003300870A5 JP2003300870A5 (en) | 2005-11-10 |
| JP4429590B2 JP4429590B2 (en) | 2010-03-10 |
Family
ID=29405037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002335272A Expired - Lifetime JP4429590B2 (en) | 2002-02-08 | 2002-11-19 | Ubiquinone-containing water-soluble composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4429590B2 (en) |
Cited By (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004064543A1 (en) * | 2003-01-17 | 2004-08-05 | Taiyo Kagaku Co., Ltd. | Compositions containing coenzyme q10 |
| WO2004080208A1 (en) * | 2003-03-11 | 2004-09-23 | Kaneka Corporation | Oil-in-water type emulsion containing coenzyme q10 and process for producing the same |
| JP2005247789A (en) * | 2004-03-05 | 2005-09-15 | Sugarlady Honsha:Kk | Royal jelly preparation |
| WO2006022187A1 (en) * | 2004-08-24 | 2006-03-02 | Nisshin Pharma Inc. | Coenzyme q10-containing composition |
| WO2006035900A1 (en) * | 2004-09-29 | 2006-04-06 | San-Ei Gen F.F.I., Inc. | Coenzyme q10-containing emulsified composition |
| JP2006141247A (en) * | 2004-11-17 | 2006-06-08 | Nisshin Pharma Inc | Medium composition for cell culture containing coenzyme q10 |
| JP2006217807A (en) * | 2005-02-08 | 2006-08-24 | Yakult Honsha Co Ltd | Food and drink |
| JP2006241075A (en) * | 2005-03-03 | 2006-09-14 | Kose Corp | Transparent aqueous composition |
| JP2007153866A (en) * | 2005-11-09 | 2007-06-21 | Yoshida Kikai Co Ltd | Emulsion type cosmetic |
| WO2008044659A1 (en) | 2006-10-06 | 2008-04-17 | Kaneka Corporation | Highly absorbable composition for oral administration containing oxidized coenzyme q10 |
| JP2008094806A (en) * | 2006-10-16 | 2008-04-24 | Freunt Ind Co Ltd | Highly water-dispersible powder and its manufacturing method |
| WO2008053920A1 (en) | 2006-10-31 | 2008-05-08 | Kaneka Corporation | Physiologically active substance-containing granular composition and method of producing the same |
| JP2008520563A (en) * | 2004-11-16 | 2008-06-19 | バイオアバイラビリティ，インク． | High concentration self-microemulsifying coenzyme Q10 preparation for nutritional use |
| WO2008088037A1 (en) * | 2007-01-18 | 2008-07-24 | National University Corporation Chiba University | Finely particulate medicinal preparation |
| JP2008239580A (en) * | 2007-03-28 | 2008-10-09 | Fujifilm Corp | Emulsion composition, and food and cosmetic containing the same |
| EP2062574A1 (en) * | 2006-09-08 | 2009-05-27 | Kaneka Corporation | Composition comprising reduced coenzyme q10 and lysolecithin |
| JP2009207384A (en) * | 2008-03-03 | 2009-09-17 | T Hasegawa Co Ltd | Emulsion composition for coenzyme q10-containing beverage, and method for producing the same |
| US20100092560A1 (en) * | 2007-04-16 | 2010-04-15 | Kaneka Corporation | Reduced coenzyme q10-containing particulate composition and method for producing the same |
| JP2010235563A (en) * | 2009-03-31 | 2010-10-21 | Fancl Corp | Emulsion composition for soft capsule and soft capsule agent |
| JP2011012003A (en) * | 2009-07-01 | 2011-01-20 | Fancl Corp | Emulsion composition for soft capsule and soft capsule |
| EP2417970A2 (en) * | 2009-04-06 | 2012-02-15 | Korea Research Institute of Bioscience and Biotechnology | Coenzyme q10 nanoparticles, preparation method thereof and composition containing said nanoparticles |
| JP2012180337A (en) * | 2011-02-10 | 2012-09-20 | Fancl Corp | Self-emulsifying preparation |
| US8388950B2 (en) | 2005-06-15 | 2013-03-05 | Kaneka Corporation | Coenzyme Q10-containing water-soluble composition and process for production thereof |
| JP2013121931A (en) * | 2011-12-12 | 2013-06-20 | Fancl Corp | Preparation containing sterol glycoside |
| JP5250258B2 (en) * | 2005-04-20 | 2013-07-31 | 中外製薬株式会社 | Design method for self-emulsifying formulation |
| JP2016517867A (en) * | 2013-04-23 | 2016-06-20 | ズィーエックス ファーマ，エルエルシー | Enteric multiparticulate composition having proteinaceous subcoat |
| JP2016128514A (en) * | 2009-08-12 | 2016-07-14 | シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
| JP2016526562A (en) * | 2013-07-11 | 2016-09-05 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドＴａｓｌｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． | Herbal medicine compositions and their formulations and uses |
| JP2017210425A (en) * | 2016-05-24 | 2017-11-30 | 公立大学法人横浜市立大学 | Magnetic polymer micelle |
| US11013694B2 (en) | 2013-07-11 | 2021-05-25 | Tasly Pharmaceutical Group Co., Ltd. | Formulation of a micro drop pill and the preparation method thereof |
| USRE49050E1 (en) | 2013-07-11 | 2022-04-26 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and preparation and application thereof |
-
2002
- 2002-11-19 JP JP2002335272A patent/JP4429590B2/en not_active Expired - Lifetime
Cited By (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004064543A1 (en) * | 2003-01-17 | 2004-08-05 | Taiyo Kagaku Co., Ltd. | Compositions containing coenzyme q10 |
| US8758743B2 (en) | 2003-01-17 | 2014-06-24 | Taiyo Kagaku Co., Ltd. | Compositions containing coenzyme Q10 |
| WO2004080208A1 (en) * | 2003-03-11 | 2004-09-23 | Kaneka Corporation | Oil-in-water type emulsion containing coenzyme q10 and process for producing the same |
| JP2005247789A (en) * | 2004-03-05 | 2005-09-15 | Sugarlady Honsha:Kk | Royal jelly preparation |
| JP4842824B2 (en) * | 2004-08-24 | 2011-12-21 | 日清ファルマ株式会社 | Coenzyme Q10-containing composition |
| US8119113B2 (en) | 2004-08-24 | 2012-02-21 | Nisshin Pharma, Inc. | Coenzyme Q10—containing composition |
| WO2006022187A1 (en) * | 2004-08-24 | 2006-03-02 | Nisshin Pharma Inc. | Coenzyme q10-containing composition |
| JPWO2006022187A1 (en) * | 2004-08-24 | 2008-05-08 | 日清ファルマ株式会社 | Coenzyme Q10-containing composition |
| JPWO2006035900A1 (en) * | 2004-09-29 | 2008-05-15 | 三栄源エフ・エフ・アイ株式会社 | Coenzyme Q10-containing emulsion composition |
| JP5147239B2 (en) * | 2004-09-29 | 2013-02-20 | 三栄源エフ・エフ・アイ株式会社 | Coenzyme Q10-containing emulsion composition |
| WO2006035900A1 (en) * | 2004-09-29 | 2006-04-06 | San-Ei Gen F.F.I., Inc. | Coenzyme q10-containing emulsified composition |
| JP2008520563A (en) * | 2004-11-16 | 2008-06-19 | バイオアバイラビリティ，インク． | High concentration self-microemulsifying coenzyme Q10 preparation for nutritional use |
| US8961958B2 (en) | 2004-11-16 | 2015-02-24 | Bioavailability, Inc | High concentration self-microemulsifying coenzyme Q10 preparations for nutritional use |
| JP2006141247A (en) * | 2004-11-17 | 2006-06-08 | Nisshin Pharma Inc | Medium composition for cell culture containing coenzyme q10 |
| JP2006217807A (en) * | 2005-02-08 | 2006-08-24 | Yakult Honsha Co Ltd | Food and drink |
| JP2006241075A (en) * | 2005-03-03 | 2006-09-14 | Kose Corp | Transparent aqueous composition |
| JP5250258B2 (en) * | 2005-04-20 | 2013-07-31 | 中外製薬株式会社 | Design method for self-emulsifying formulation |
| JP5199665B2 (en) * | 2005-06-15 | 2013-05-15 | 株式会社カネカ | Coenzyme Q10-containing water-soluble composition and process for producing the same |
| US8388950B2 (en) | 2005-06-15 | 2013-03-05 | Kaneka Corporation | Coenzyme Q10-containing water-soluble composition and process for production thereof |
| JP2007153866A (en) * | 2005-11-09 | 2007-06-21 | Yoshida Kikai Co Ltd | Emulsion type cosmetic |
| EP2062574A1 (en) * | 2006-09-08 | 2009-05-27 | Kaneka Corporation | Composition comprising reduced coenzyme q10 and lysolecithin |
| EP2062574A4 (en) * | 2006-09-08 | 2011-01-05 | Kaneka Corp | Composition comprising reduced coenzyme q10 and lysolecithin |
| WO2008044659A1 (en) | 2006-10-06 | 2008-04-17 | Kaneka Corporation | Highly absorbable composition for oral administration containing oxidized coenzyme q10 |
| JP5352235B2 (en) * | 2006-10-06 | 2013-11-27 | 株式会社カネカ | Superabsorbent oral composition containing oxidized coenzyme Q10 |
| WO2008047559A1 (en) * | 2006-10-16 | 2008-04-24 | Freund Corporation | Highly water-dispersible powder and method of producing the same |
| JP2008094806A (en) * | 2006-10-16 | 2008-04-24 | Freunt Ind Co Ltd | Highly water-dispersible powder and its manufacturing method |
| WO2008053920A1 (en) | 2006-10-31 | 2008-05-08 | Kaneka Corporation | Physiologically active substance-containing granular composition and method of producing the same |
| WO2008088037A1 (en) * | 2007-01-18 | 2008-07-24 | National University Corporation Chiba University | Finely particulate medicinal preparation |
| JP2008239580A (en) * | 2007-03-28 | 2008-10-09 | Fujifilm Corp | Emulsion composition, and food and cosmetic containing the same |
| US20100092560A1 (en) * | 2007-04-16 | 2010-04-15 | Kaneka Corporation | Reduced coenzyme q10-containing particulate composition and method for producing the same |
| JP2009207384A (en) * | 2008-03-03 | 2009-09-17 | T Hasegawa Co Ltd | Emulsion composition for coenzyme q10-containing beverage, and method for producing the same |
| JP2010235563A (en) * | 2009-03-31 | 2010-10-21 | Fancl Corp | Emulsion composition for soft capsule and soft capsule agent |
| EP2417970A4 (en) * | 2009-04-06 | 2012-10-10 | Korea Res Inst Of Bioscience | Coenzyme q10 nanoparticles, preparation method thereof and composition containing said nanoparticles |
| JP2012522835A (en) * | 2009-04-06 | 2012-09-27 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | Coenzyme Q10 nanoparticles, method for producing the same, and compositions containing the nanoparticles |
| EP2417970A2 (en) * | 2009-04-06 | 2012-02-15 | Korea Research Institute of Bioscience and Biotechnology | Coenzyme q10 nanoparticles, preparation method thereof and composition containing said nanoparticles |
| JP2011012003A (en) * | 2009-07-01 | 2011-01-20 | Fancl Corp | Emulsion composition for soft capsule and soft capsule |
| JP2016128514A (en) * | 2009-08-12 | 2016-07-14 | シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
| JP2012180337A (en) * | 2011-02-10 | 2012-09-20 | Fancl Corp | Self-emulsifying preparation |
| JP2013121931A (en) * | 2011-12-12 | 2013-06-20 | Fancl Corp | Preparation containing sterol glycoside |
| JP2016517867A (en) * | 2013-04-23 | 2016-06-20 | ズィーエックス ファーマ，エルエルシー | Enteric multiparticulate composition having proteinaceous subcoat |
| JP2016526562A (en) * | 2013-07-11 | 2016-09-05 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドＴａｓｌｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． | Herbal medicine compositions and their formulations and uses |
| US11013694B2 (en) | 2013-07-11 | 2021-05-25 | Tasly Pharmaceutical Group Co., Ltd. | Formulation of a micro drop pill and the preparation method thereof |
| USRE49035E1 (en) | 2013-07-11 | 2022-04-19 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and preparation and application thereof |
| USRE49050E1 (en) | 2013-07-11 | 2022-04-26 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and preparation and application thereof |
| JP2017210425A (en) * | 2016-05-24 | 2017-11-30 | 公立大学法人横浜市立大学 | Magnetic polymer micelle |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4429590B2 (en) | 2010-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4429590B2 (en) | Ubiquinone-containing water-soluble composition | |
| CN101534796B (en) | Physiologically active substance-containing granular composition and method of producing the same | |
| EP2846768B1 (en) | Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate | |
| JP4815053B2 (en) | Microemulsions as solid dosage forms for oral administration | |
| JP5343002B2 (en) | Bioactive substance-containing composition | |
| CN101309688B (en) | The compositions of sustained release Beta-alanine and method | |
| JP5140585B2 (en) | Reduced coenzyme Q10-containing composition and method for producing the same | |
| CN1741748A (en) | Pulverulent phytosterol formulations | |
| US20170216224A1 (en) | Solid particulate compositions comprising coenzyme q10 | |
| EP1806129A1 (en) | Composition containing fine particles and process for producing the same | |
| JP2004514419A (en) | Method for producing water-dispersible compound containing carotenoid | |
| AU2022202308A1 (en) | Ubiquinone and ubiquinol compositions, and methods relating thereto | |
| JPH0474339B2 (en) | ||
| JP3996691B2 (en) | Emulsified powder and method for producing the same | |
| AU2015351685B2 (en) | Disintegrative particle composition including pulverized lactose or granulated lactose | |
| JP2004242509A (en) | Food containing coenzyme q10 and amino acid | |
| JP2005187405A (en) | Uric acid value inhibitor and purine body adsorbent | |
| US9399020B2 (en) | Hydrophilic matrix beadlet compositions with enhanced bioavailability | |
| JP3948872B2 (en) | Vitamin preparation | |
| JP2006089381A (en) | Method for producing ubidecarenone-containing microcapsule | |
| JP2003221329A (en) | Dry syrup containing branched amino acids | |
| JP2002154949A (en) | Solid preparation for internal use | |
| JP2004331597A (en) | New composition and method for producing the same | |
| JP2020180093A (en) | Powder composition containing reduced coenzyme q10 and antioxidant | |
| WO2021171068A1 (en) | Mct absorbate composition and process for preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050906 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050906 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050829 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090413 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090630 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090820 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090929 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091215 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091216 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121225 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4429590 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121225 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131225 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |